Please assess the completion status of the following clinical trial:

Trial Title: Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD6918

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced solid tumors for which standard treatment does not exist or is no longer effective.~* For chemotherapy combination treatment, must be suitable for treatment with either gemcitabine or pemetrexed.~* Relatively good overall health other than cancer.~Exclusion Criteria:~* Poor bone marrow function (not producing enough blood cells).~* Poor liver or kidney function.~* Serious heart conditions~* History of uncontrolled epilepsy, Parkinson's disease, Alzheimer's disease, brain tumor or any uncontrolled psychiatric or nervous system condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gemcitabine (Type: EXPERIMENTAL): gemcitabine administered in combination with AZD6918
- pemetrexed (Type: EXPERIMENTAL): pemetrexed administered in combination with AZD6918
- AZD6918 (Type: EXPERIMENTAL): AZD6918 administered alone

Based on this trial design, predict the completion outcome and termination type (if applicable).